Icenticaftor

mutant + WT CFTR Cl channel potentiator

oral 300 mg BID , Ph. II in COPD and CF

from 1M cmpd cell-based HTS + opt.

J. Med. Chem., May 24, 2021

Millenium/Takeda, Cambridge, MA

The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause…

become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

Stay up-to-date and save more time with exclusive members-only content
On-board new team members with educational content and case studies

Generate ideas and discussion with easy-to-read slide decks
Generate ideas and discussion with easy-to-read slide decks